Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Moleculin Biotech stock | $3.7

Learn how to easily invest in Moleculin Biotech stock.

Moleculin Biotech, Inc
NASDAQ: MBRX - USD
BIOTECHNOLOGY
$3.12
-$0.03 (-0.95%)

Moleculin Biotech, Inc is a biotechnology business based in the US. Moleculin Biotech shares (MBRX) are listed on the NASDAQ and all prices are listed in US Dollars. Moleculin Biotech employs 10 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Moleculin Biotech

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MBRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Moleculin Biotech stock price (NASDAQ: MBRX)

Use our graph to track the performance of MBRX stocks over time.

Moleculin Biotech shares at a glance

Information last updated 2021-07-28.
Latest market close$3.70
52-week range$3.10 - $8.78
50-day moving average $3.58
200-day moving average $4.10
Wall St. target price$20.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.32

Buy Moleculin Biotech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Moleculin Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Moleculin Biotech price performance over time

Historical closes compared with the close of $3.7 from 2021-05-28

1 week (2021-07-23) N/A
1 month (2021-07-02) 3.93%
3 months (2021-05-03) 2.21%
6 months (2021-01-30) N/A
1 year (2020-07-30) N/A
2 years (2019-07-30) N/A
3 years (2018-07-30) N/A
5 years (2016-07-30) N/A

Moleculin Biotech financials

Gross profit TTM $0
Return on assets TTM -20.73%
Return on equity TTM -39.67%
Profit margin 0%
Book value $3.11
Market capitalisation $91.1 million

TTM: trailing 12 months

Shorting Moleculin Biotech shares

There are currently 949,859 Moleculin Biotech shares held short by investors – that's known as Moleculin Biotech's "short interest". This figure is 1% down from 959,289 last month.

There are a few different ways that this level of interest in shorting Moleculin Biotech shares can be evaluated.

Moleculin Biotech's "short interest ratio" (SIR)

Moleculin Biotech's "short interest ratio" (SIR) is the quantity of Moleculin Biotech shares currently shorted divided by the average quantity of Moleculin Biotech shares traded daily (recently around 303469.32907348). Moleculin Biotech's SIR currently stands at 3.13. In other words for every 100,000 Moleculin Biotech shares traded daily on the market, roughly 3130 shares are currently held short.

However Moleculin Biotech's short interest can also be evaluated against the total number of Moleculin Biotech shares, or, against the total number of tradable Moleculin Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Moleculin Biotech's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Moleculin Biotech shares in existence, roughly 30 shares are currently held short) or 0.0341% of the tradable shares (for every 100,000 tradable Moleculin Biotech shares, roughly 34 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Moleculin Biotech.

Find out more about how you can short Moleculin Biotech stock.

Moleculin Biotech share dividends

We're not expecting Moleculin Biotech to pay a dividend over the next 12 months.

Have Moleculin Biotech's shares ever split?

Moleculin Biotech's shares were split on a 1:6 basis on 31 January 2021. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Moleculin Biotech shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Moleculin Biotech shares which in turn could have impacted Moleculin Biotech's share price.

Moleculin Biotech share price volatility

Over the last 12 months, Moleculin Biotech's shares have ranged in value from as little as $3.1 up to $8.78. A popular way to gauge a stock's volatility is its "beta".

MBRX.US volatility(beta: 1.97)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moleculin Biotech's is 1.9684. This would suggest that Moleculin Biotech's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Moleculin Biotech overview

Moleculin Biotech, Inc. , a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses in the United States. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and hematologic malignancies. It also develops WP1220, an analog of WP1066, which has completed Phase 1 clinical trial for the topical treatment of cutaneous T-cell lymphoma in Poland; WP1234 for the treatment of pancreatic cancer; and WP1732, an analog of WP1066 for the treatment of topical treatment of cutaneous T-cell lymphoma. The company's lead metabolism/glycosylation inhibitor compound is WP1122 to treat cancers and viruses. In addition, it engages in the preclinical development of other drug candidates, including other immune/transcription modulators and antimetabolites, targeting glycolysis and glycosylation.

Stocks similar to Moleculin Biotech

Frequently asked questions

What percentage of Moleculin Biotech is owned by insiders or institutions?
Currently 2.056% of Moleculin Biotech shares are held by insiders and 13.68% by institutions.
How many people work for Moleculin Biotech?
Latest data suggests 10 work at Moleculin Biotech.
When does the fiscal year end for Moleculin Biotech?
Moleculin Biotech's fiscal year ends in December.
Where is Moleculin Biotech based?
Moleculin Biotech's address is: 5300 Memorial Drive, Houston, TX, United States, 77007
What is Moleculin Biotech's ISIN number?
Moleculin Biotech's international securities identification number is: US60855D1019
What is Moleculin Biotech's CUSIP number?
Moleculin Biotech's Committee on Uniform Securities Identification Procedures number is: 60855D101

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site